

Role of 18F-FDG PET/CT in Staging and Follow up of Lymphoma in Pediatric and Young Adult Patients.

Thesis

***Submitted in partial fulfillment of M.D. in
Nuclear Medicine***

By

Rehab Ahmad Abd El Meguid, M.Sc.

*Assistant Lecturer of Nuclear Medicine
Cairo University*

Supervisors

Hosna Mohamed Moustafa, M.D.

*Professor of Nuclear Medicine
Faculty of Medicine
Cairo University*

Walid Soliman Omar, M.D.

*Professor of Nuclear Medicine
National Cancer Institute
Cairo University*

Yasser Mohamed Ahmed, M.D.

*Lecturer of Nuclear Medicine
Faculty of Medicine
Cairo University*

**Faculty of Medicine
Cairo University
2012**

Abstract

The study was conducted at the Children's Cancer Hospital in Cairo. A total of sixty two patients who performed one hundred and fifty five PET/CT studies (17 girls and 45 boys) with histologically proven malignant lymphoma (56 HD, 6 NHL) were included in this study. They were divided into four groups according to the indication of PET/CT study. Group I: 62 studies for initial staging. Group II: 35 studies for evaluating early treatment response after two to three cycles of chemotherapy. Group III: 27 studies for evaluating treatment response 4–8 weeks after the end of their treatment. Group IV: 30 studies evaluated for follow-up and detection of relapse. Results of PET/CT were compared with diagnostic CT.

Key word:

Nuclear- Lymphoma-18F-FDG-PET/CT

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

اقْرَأْ بِاسْمِ رَبِّكَ الَّذِي خَلَقَ * خَلَقَ الْإِنْسَانَ مِنْ عَلَقٍ * اقْرَأْ

وَرَبُّكَ الْأَكْرَمُ * الَّذِي عَلَّمَ بِالْقَلَمِ * عَلَّمَ الْإِنْسَانَ مَا لَمْ يَعْلَمْ *

صدق الله العظيم

سورة العلق، الآيات 1-5

Acknowledgements

I was fortunate to carry this work under the guidance of Prof. Dr. Hosna Mohamed Moustafa, professor of nuclear medicine, faculty of medicine, Cairo University, who offered me a lot of her time and experience. She contributed greatly to bring this work to its form through her suggestions, valuable observations and meticulous revision of every possible detail. To her I owe what is beyond expression.

I would like to express my profound and sincere appreciation to Prof. Dr. Walid Soliman Omar, professor of nuclear medicine, national cancer institute, Cairo University, for his most valuable advice, continuous encouragement, and indispensable guidance. For him, no words of gratitude are sufficient.

Many thanks to Dr. Yasser Mohamed Ahmed, lecturer of nuclear medicine, faculty of medicine, Cairo University, for his kindness and encouragement.

Also, I would like to thank all the staff members of the nuclear medicine unit in the children's cancer hospital for helping me with my research work and providing me with clinical and follow up data. They gave me a great opportunity to conduct my research in a warm and friendly environment.

Table of Contents

Acknowledgements.....	i
Table of Contents.....	ii
List of Figures	v
List of Tables	ix
List of Abbreviations	xii
Introduction.....	1
Aim of the Work	3
Epidemiology of Pediatric Lymphoma.....	4
Incidence.....	4
Risk factors.....	5
Pathology of Pediatric Lymphoma.....	10
Hodgkin’s disease.....	10
Non-Hodgkin’s Lymphoma.....	15
Staging of Lymphoma.....	28
Diagnosis and Evaluation of the Child with Lymphoma.....	29
Clinical assessment.....	29
Pathologic Diagnosis.....	31
Laboratory Studies.....	31
Bone marrow biopsy.....	31
Imaging Studies.....	33
PET/CT Imaging.....	45
PET/CT System.....	45
Radiopharmacy.....	53

FDG PET/CT Imaging Protocol.....	56
Image interpretation.....	62
Normal Pattern.....	66
Limitations and Artifacts.....	67
Clinical Role of PET/CT in Lymphoma.....	74
I. Initial Staging.....	74
II. Assessment of Therapeutic Response.....	91
III. Stem Cell Transplantation.....	108
IV. Surveillance during Follow Up.....	109
Treatment Outline for Pediatric Lymphoma.....	110
Patients and Methods.....	119
Patients.....	119
PET/CT Imaging Protocol.....	120
Data interpretation and analysis.....	121
Calculation of standard uptake value.....	122
Therapy.....	122
Follow up protocol.....	123
Statistical Analysis.....	123
Results.....	127
Description of the studied patients.....	127
Patients Groups.....	133
Group I.....	133
Group II.....	137
Group III.....	146
Group IV.....	155
Case Presentation.....	164

Case 1: Lymphoma initial staging.....	164
Case 2: Lymphoma initial staging.....	165
Case 3: Lymphoma early response to therapy.....	166
Case 4: Lymphoma delayed response to therapy.....	169
Case 5: Relapsing lymphoma.....	172
Case 6: Recurrent HD.....	175
Discussion	179
Conclusion and Recommendations.....	186
Summary	187
References.....	190
Arabic summary.....	204

List of Figures

Figure 1: Classic Hodgkin's Lymphoma.....	11
Figure 2: Burkitt Lymphoma.....	20
Figure 3: Diffuse large B-cell lymphoma.....	22
Figure 4: Anaplastic large cell lymphoma, classic type.....	25
Figure 5: Hepatosplenic T-cell lymphoma.....	27
Figure 6: Bone marrow biopsy: large B cell lymphoma infiltration.....	32
Figure 7: Chest X-ray showing pulmonary infiltration by DLBC NHL.....	33
Figure 8: Staging CT scan of the abdomen in a patient with HD.....	35
Figure 9: Residual mass.....	39
Figure 10: MRI images of the pelvis in a patient with NHL.....	41
Figure 11: Gallium-67 citrate total body imaging.....	44
Figure 12: Positron–electron annihilation reaction.....	46
Figure 13: Electronic collimation.....	47
Figure 14: Scatter coincidence.....	48
Figure 15: True coincidence.....	48
Figure 16: Formation of CT images.....	51
Figure 17: Schematic of design concept of combined PET/CT scanner.....	52
Figure 18: Mechanism of FDG uptake.....	55
Figure 19: A typical combined PET/CT protocol.....	61
Figure 20: Normal PET/CT scan.....	67
Figure 21: Intense diffuse symmetrical muscular uptake.....	68

Figure 22: Muscle uptake and effect of oral anxiolytics.....	68
Figure 23: Brown fat uptake.....	70
Figure 24: CT attenuation artifact from an implantable catheter port.....	72
Figure 25: CT attenuation artifact due to intravenous contrast material.....	72
Figure 26: Truncation artifact.....	73
Figure 27: Staging with PET/CT.....	75
Figure 28: PET/CT patterns of extranodal involvement by lymphoma.....	78
Figure 29: Patient with follicular lymphoma.....	81
Figure 30: Patient with diffuse large B-cell lymphoma.....	83
Figure 31: Patient with cutaneous T-cell lymphoma.....	86
Figure 32: Patterns of bone marrow involvement by lymphoma.....	89
Figure 33: Pattern of splenic involvement by lymphoma.....	95
Figure 34: Assessment of early response to treatment.....	99
Figure 35: Reevaluation with PET/CT after chemotherapy.....	102
Figure 36: False-positive PET/CT findings.....	105
Figure 37: Demographic characteristics of the studied group.....	127
Figure 38: Pathology of the studied group.....	128
Figure 39: Pathology subtype of the studied group.....	129
Figure 40: B symptoms among the studied group.....	131
Figure 41: ESR among the studied group.....	131
Figure 42: Nodal involvement among the studied group.....	132
Figure 43: Extranodal affection among the studied group.....	132
Figure 44: SUV among the studied group.....	133

Figure 45: Initial staging by CT versus PET CT among studied group....	134
Figure 46: Staging results of PET CT in relation to CT.....	135
Figure 47: Agreement between CT and PET CT results at initial staging.	136
Figure 48: Early assessment by CT versus PET CT among studied group.....	137
Figure 49: Follow up of the studied group at early assessment.....	138
Figure 50: Agreement between CT and PET CT results at early assessment.....	139
Figure 51: CT results at early assessment of response to therapy.....	140
Figure 52: PET CT results at early assessment of response to therapy.....	141
Figure 53: Delayed assessment by CT versus PET CT among studied group.....	146
Figure 54: Follow up of the studied group at delayed assessment.....	147
Figure 55: Agreement between CT and PET CT results at delayed assessment of response to therapy	148
Figure 56: CT results delayed assessment of response to therapy.....	149
Figure 57: PET/CT results at delayed assessment of response to therapy.	150
Figure 58: Relapse assessment by CT versus PET CT among studied group.....	155
Figure 59: Follow up of the studied group at 3-12 months.....	156
Figure 60: Agreement between CT and PET CT results for relapse.....	157
Figure 61: CT results at detection of relapse.....	158
Figure 62: PET/CT results for detection of relapse.....	159
Figure 63: Case 1: Lymphoma initial staging.....	164

Figure 64: Case 2: Lymphoma initial staging.....	165
Figure 65: Case 3: Lymphoma early response to therapy.....	167
Figure 66: Case 4: Lymphoma delayed response to therapy.....	170
Figure 67: Case 5: Relapsing lymphoma.....	173
Figure 68: Case 6: Recurrent HD.....	176

List of Tables

Table 1: WHO classification of lymphoid neoplasms.....	16
Table 2: Comparative features of the most common pediatric lymphoma types.....	17
Table 3: Ann Arbor Staging Classification.....	28
Table 4: RECIST criteria for assessment of response.....	37
Table 5: 18F-FDG Radiation Dosimetry for Children.....	58
Table 6: International Harmonization Project Criteria for Assessment of Response to Therapy for Lymphoma.....	93
Table 7: Chemotherapy regimens for Hodgkin lymphoma.....	111
Table 8: Recommended therapy for early-stage NHL.....	117
Table 9: Recommended therapy for advanced-stage NHL.....	118
Table 10: Demographic characteristics of the studied group.....	127
Table 11: Pathology of the studied group.....	128
Table 12: Pathology subtype of the studied group.....	129
Table 13: Distribution of certain factors among the studied group.....	130
Table 14: Initial staging by CT versus PET CT among studied group.....	134
Table 15: Staging results of PET CT in relation to CT.....	135
Table 16: Agreement between CT and PET CT results at initial staging...	136
Table 17: Early assessment by CT versus PET CT among studied group...	137
Table 18: Follow up of the studied group at early assessment.....	138
Table 19: Agreement between CT and PET CT results at early assessment of response to therapy.....	139
Table 20: Measures of sensitivity, specificity, PPV & NPV of diagnostic CT in detecting remission at early assessment of response to therapy.....	140

Table 21: Measures of sensitivity, specificity, PPV & NPV of PET/CT in detecting remission at early assessment of response to therapy.....	141
Table 22: Relation between sex and CR at early assessment of response...	142
Table 23: Relation between Age and remission of disease at early assessment.....	142
Table 24: Relation between Pathology results and Remission of disease at early assessment.....	143
Table 25: Relation between different factors and Remission of disease at early assessment.....	144
Table 26: Multivariate model of group II.....	145
Table 27: Delayed assessment by CT versus PET CT among studied group.....	146
Table 28: Follow up of the studied group at delayed assessment.....	147
Table 29: Agreement between CT and PET CT results at delayed assessment of response to therapy.....	148
Table 30: Measures of sensitivity, specificity, PPV & NPV of CT in detecting remission at delayed assessment of response to therapy.....	149
Table 31: Measures of sensitivity, specificity, PPV & NPV of PET/CT in detecting remission at delayed assessment of response to therapy.....	150
Table 32: Relation between sex and Remission of disease at delayed assessment.....	151
Table 33: Relation between Age and remission of disease at delayed assessment.....	151
Table 34: Relation between Pathology results and remission of disease at delayed assessment.....	152
Table 35: Relation between different factors and Remission of disease at delayed assessment.....	153
Table 36: Multivariate model of Group III.....	154
Table 37: Relapse assessment by CT versus PET CT among studied group.....	155

Table 38: Follow up of the studied group at 3-12 months.....	156
Table 39: Agreement between CT and PET CT results for relapse.....	157
Table 40: Measures of sensitivity, specificity, PPV & NPV CT in detecting relapse.....	158
Table 41: Measures of sensitivity, specificity, PPV & NPV CT in detecting relapse.....	159
Table 42: Sensitivity, specificity, accuracy, PPV, NPV of CT and PET/CT of various groups in the study.....	160
Table 43: Relation between sex and relapse of disease.....	160
Table 44: Relation between age and relapse of disease.....	160
Table 45: Relation between pathology results and relapse of disease.....	161
Table 46: Relation between different risk factors and relapse of disease...	162
Table 47: Multivariate model of group IV.....	163

List of Abbreviations

HD: Hodgkin's disease.

HL: Hodgkin's lymphoma.

NHL: Non-Hodgkin's lymphoma.

GPCR: Gharbia population based cancer registry.

EBV: Epstein-Barr virus.

OR: Odds ratio.

HIV: Human immunodeficiency virus.

PTLD: Posttransplant lymphoproliferative disease.

RS: Reed-Sternberg cell.

NSHL: Nodular sclerosis Hodgkin lymphoma.

MCHL: Mixed cellularity Hodgkin lymphoma.

ALCL: Anaplastic large cell lymphoma.

LRCHL: Lymphocyte rich classic Hodgkin lymphoma.

LDHL: Lymphocyte-depleted Hodgkin lymphoma.

LPHL: Lymphocyte predominance Hodgkin lymphoma.

WHO: World Health Organization.

REAL: Revised European-American Lymphoma.

DLBCL: Diffuse large B-cell lymphoma.

ALL: Acute lymphocytic leukemia.

AML: Acute myeloid leukemia.

ESR: Erythrocyte sedimentation rate.